322 related articles for article (PubMed ID: 25670082)
21. Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.
Sredni ST; Gadd S; Huang CC; Breslow N; Grundy P; Green DM; Dome JS; Shamberger RC; Beckwith JB; Perlman EJ;
Clin Cancer Res; 2009 Nov; 15(22):6800-9. PubMed ID: 19903788
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
[TBL] [Abstract][Full Text] [Related]
23. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
Gadd S; Huff V; Walz AL; Ooms AHAG; Armstrong AE; Gerhard DS; Smith MA; Auvil JMG; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Hermida LC; Davidsen T; Gesuwan P; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Dome JS; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Ross N; Gastier-Foster JM; Arold ST; Perlman EJ
Nat Genet; 2017 Oct; 49(10):1487-1494. PubMed ID: 28825729
[TBL] [Abstract][Full Text] [Related]
24. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex.
Cheng TL; Wang Z; Liao Q; Zhu Y; Zhou WH; Xu W; Qiu Z
Dev Cell; 2014 Mar; 28(5):547-60. PubMed ID: 24636259
[TBL] [Abstract][Full Text] [Related]
25. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of microRNA processing enzymes Drosha and Dicer in gestational diabetes mellitus.
Rahimi G; Jafari N; Khodabakhsh M; Shirzad Z; Dogaheh HP
Gynecol Endocrinol; 2015 Feb; 31(2):156-9. PubMed ID: 25295740
[TBL] [Abstract][Full Text] [Related]
27. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.
Hing S; Lu YJ; Summersgill B; King-Underwood L; Nicholson J; Grundy P; Grundy R; Gessler M; Shipley J; Pritchard-Jones K
Am J Pathol; 2001 Feb; 158(2):393-8. PubMed ID: 11159177
[TBL] [Abstract][Full Text] [Related]
28. Functional Anatomy of the Human Microprocessor.
Nguyen TA; Jo MH; Choi YG; Park J; Kwon SC; Hohng S; Kim VN; Woo JS
Cell; 2015 Jun; 161(6):1374-87. PubMed ID: 26027739
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors.
Rakheja D; Khokhar S; Mitui M; Cost NG
Pediatr Dev Pathol; 2012; 15(4):286-92. PubMed ID: 22483234
[TBL] [Abstract][Full Text] [Related]
31. TP53 codon 72 polymorphisms in favorable histology Wilms tumors.
Cost NG; Mitui M; Khokhar S; Wickiser JE; Baker LA; Rakheja D
Pediatr Blood Cancer; 2012 Aug; 59(2):326-8. PubMed ID: 22052810
[TBL] [Abstract][Full Text] [Related]
32. Imprinting, expression, and localisation of DLK1 in Wilms tumours.
Fukuzawa R; Heathcott RW; Morison IM; Reeve AE
J Clin Pathol; 2005 Feb; 58(2):145-50. PubMed ID: 15677533
[TBL] [Abstract][Full Text] [Related]
33. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
Brown KW; Power F; Moore B; Charles AK; Malik KT
Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
[TBL] [Abstract][Full Text] [Related]
34. Impaired expression of Drosha in breast cancer.
Poursadegh Zonouzi AA; Shekari M; Nejatizadeh A; Shakerizadeh S; Fardmanesh H; Poursadegh Zonouzi A; Rahmati-Yamchi M; Tozihi M
Breast Dis; 2017; 37(2):55-62. PubMed ID: 28598829
[TBL] [Abstract][Full Text] [Related]
35. Loss of Dgcr8-mediated microRNA expression in the kidney results in hydronephrosis and renal malformation.
Bartram MP; Dafinger C; Habbig S; Benzing T; Schermer B; Müller RU
BMC Nephrol; 2015 Apr; 16():55. PubMed ID: 25881298
[TBL] [Abstract][Full Text] [Related]
36. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
37. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.
Wittmann S; Zirn B; Alkassar M; Ambros P; Graf N; Gessler M
Genes Chromosomes Cancer; 2007 Feb; 46(2):163-70. PubMed ID: 17099873
[TBL] [Abstract][Full Text] [Related]
38. Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor.
Breslow NE; Beckwith JB; Perlman EJ; Reeve AE
Pediatr Blood Cancer; 2006 Sep; 47(3):260-7. PubMed ID: 16700047
[TBL] [Abstract][Full Text] [Related]
39. Single-nucleotide polymorphism in WT1 gene in a hyperplastic intralobar nephrogenic rest with botryoid protrusion.
Mizuno K; Hayashi Y; Tozawa K; Iwatsuki S; Kojima Y; Kohri K
Urology; 2010 Jul; 76(1):149-52. PubMed ID: 19914700
[TBL] [Abstract][Full Text] [Related]
40. SIX1 protein expression selectively identifies blastemal elements in Wilms tumor.
Sehic D; Karlsson J; Sandstedt B; Gisselsson D
Pediatr Blood Cancer; 2012 Jul; 59(1):62-8. PubMed ID: 22180226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
